It has been made certain that Goldman Sachs has downgraded Boston Scientific which resulted in their shares plummeting down by almost 2.8 per cent and went down to about $6.60 in the premarket trading on Tuesday and it is a notable fact that the stock of the Boston Scientific had closed on Monday at about $6.80 which recorded a slump of about 12.6 per cent.

The decision from Goldman Sachs to slash its recommendation for the firm was right after their announcement that they were planning to put an end to the shipping of a few defibrillators as a few errors were made in the documentation in the filing of the Food and Drug Administration.

It was also reported that those devices actually made up more than 15 per cent of the total revenue of the company. Due to this move, they were cut to the stage of conviction sell from the earlier neutral. As the company is retrieving the inventories and also stopped the shipment, the resulting impact will not only affect the sale but also the brand loyalty which will also impact the physicians.